GBG Research at SABCS Virtual Meeting 2020

Penelope-B

GS1-02 Oral presentation Wednesday, December 9, 2020. General Session 1
Moderator: Angela DeMichele, MD, MSCE, Time: 8:15-8-30 AM CT
Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
Loibl S, Marmé F, Martin M, et al.

DESTINY-Breast05

OT-03-01, TIP, ePoster Wednesday, December 9, 2020: 8:00 AM CT
Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05)
Geyer, Jr CE, Untch M, Prat A, et al.

APHINITY

PD3-01, Poster discussion Spotlight Poster Discussion 3 – Wednesday, December 9, 2020: 6:30 pm – 7:45 pm CT
BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
Krop I, Mittempergher L, Paulson J, et al.

PS7-21, ePoster Poster Session 7 – Wednesday, December 9, 2020: 8:00 AM CT
Timelines to initiate an adjuvant phase III trial across the globe: a sub-analysis of the APHINITY trial
Franzoi MA, Procter M, Emond O, et al.

PS10-01, ePoster Poster Session 10 – Wednesday, December 9, 2020: 8:00 AM CT
6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a STEPP analysis of the APHINITY (BIG 4-11) trial
Gelber RD, Wang XV, Cole BF, et al.

• More Information about SABCS 2020